Maxcyte Share Discussion Threads

[adamb1978] 22/1/2023 19:35

Does anyone know the date of Q4 results? Last year was 24th Jan
Thanks

[adamb1978] 04/1/2023 07:39

Nice start to the year!Hopefully help the share price given it's been weak recently

[rambutan2] 11/12/2022 20:38

It's all just amazing stuff, and brilliant that the MXCT tech is playing a part in these great advances.

[davep4] 11/12/2022 16:10

From the BBC article - "She's the first patient to be treated with this technology," said Prof Waseem Qasim, from UCL and Great Ormond Street.

Both UCL and Great Ormand Street have Maxcyte electroporation instruments.

[davep4] 11/12/2022 13:25

Nanopayments beat me to it!

[nanopayments] 11/12/2022 08:57

BEAM Therapeutics, using MaxCyte's Flow Electroporation, just got FDA approval for a clinical trial to do something very similar, just with 4 instead of 3 edits:

www.bbc.com/news/health-63859184

[edwardt] 09/12/2022 17:05

Properly exciting company that. I own it via puretech holding.

[davep4] 08/12/2022 23:47

To better understand the vor technology please watch;

[multibagger] 08/12/2022 07:03

Good morning al101uk and all :)

Early days yet but looks pretty promising IMHO...

[al101uk] 08/12/2022 00:00

Is this it?



Don't really understand the significance, but the only thing on their site from today.

[adamb1978] 07/12/2022 20:02

"impressive announcement jsut out."

nothing on RNS? What are you referring to?

[edwardt] 07/12/2022 19:50

Agreement done in 19. I am no expert but looks like they are onto something

[edwardt] 07/12/2022 16:29

impressive announcement jsut out.

[edwardt] 07/12/2022 16:28

is vor biopharma one of our spls??

[davep4] 06/12/2022 10:15

That’s 4 SPLs this year.

[rambutan2] 05/12/2022 19:18

Welcome aboard:

ROCKVILLE, MD, and SEOUL, South Korea December 5, 2022 - MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, and Curamys , a South Korean biotechnology company that develops cell & gene therapy using cell fusion technology to treat rare intractable diseases, including Duchenne muscular dystrophy and amyotrophic lateral sclerosis, today announced the signing of a strategic platform license (SPL).

Under the terms of the agreement, Curamys obtains non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation(R) technology and ExPERT(TM) platform. In return, MaxCyte is entitled to receive platform licensing fees and program-related revenue.

[nanopayments] 05/11/2022 13:58

"Investment Takeaways
● CGT production demand is likely to increase 3-5x over the next few years as approvals and launches begin to accelerate. CGT speciality providers, services, CROs and makers of devices that support production and development are about to see a huge surge in demand. Speciality CDMOs focused on CGT will also see a huge increase in volume and demand."

And MaxCyte has been investing heavily in new manufacturing capacity to take advantage of this surge in demand.

[nanopayments] 05/11/2022 13:49

"Prior to beginning the deep dive, the fund was already heavily invested in three CGT pick & shovel companies, MaxCyte, ClearPoint Neuro, and Biolife Solutions. I came away from the Deep Dive with even more conviction about the coming growth and potential of the CGT space than before. I continue to believe these three companies are poised for massive growth over the next 10 years. Here is a summary of the overall CGT thesis:
• CGT is in its infancy, but it will see S-curve growth in patient numbers in 2023 and 2024 driven by upcoming CGT treatment approvals.
• CGT requires a different production, treatment, and logistics value chain than traditional small molecules. Traditional providers have been slow to support CGT development, allowing specialty providers like MaxCyte, Clearpoint Neuro, and Biolife Solutions a high growth, high value niche, which is required by drug developers to successfully launch new CGT treatments.
• With COVID-19 largely behind the world, barriers to CGT development including slow FDA approvals and resource constraints are going away allowing CGT to blossom.
Timing-wise, everything is lining up extremely well for CGT going forward.
• Since each CGT treatment requires a different production and treatment plan, there is no standard within the industry for commercial scale production, allowing many smaller specialty tools and services companies to thrive.
• CGT will be in high demand for potential patients as it is a curative treatment for genetic disease, unlike all other treatments to date."

[nanopayments] 05/11/2022 13:44

MaxCyte is investment manager Deep Sail Capital's largest long position. Their report on the cell and gene therapy industry and their Q3 investment report are worth reading both for the comments about the wider industry and specifics on MaxCyte:
www.deepsailcapital.com/_files/ugd/50dba3_14c811dff58c4205b560cd090e285765.pdf
www.deepsailcapital.com/_files/ugd/50dba3_9d436af21a7f4c8b9d0dd2544133413d.pdf

[nanopayments] 30/10/2022 12:05

H1 2022 revenue grew 56% YoY vs revenue in H1 2021, yet management have guided for 30% revenue growth for the full year. So, will revenue in Q3 and Q4 slow vs H2 2021, or will they beat guidance? We will find out a bit more on the 9th of November when they report Q3 results.

[nanopayments] 29/9/2022 11:02

This SPL wasn't a big surprise, given Vertex is responsible for most of the manufacturing of Exa-cel (CTX001), a programme for which Crispr therapeutics had already signed an SPL. The good news for me is that tt suggests confidence on Vertex's part in SEC approval and commercialisation.

[adamb1978] 29/9/2022 08:10

Yes, that was a nice announcement by MXCT. Well known and sizeable customer

[rambutan2] 28/9/2022 23:13

Gilts down the drain, but gilt edged bio tech a winner!

ROCKVILLE , MD, September 28, 2022 -MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announces the signing of a strategic platform license (SPL) with Vertex Pharmaceuticals Incorporated, a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases.

Under the terms of the agreement, Vertex obtains non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation(R) technology and ExPERT(TM) platform in the development of its CRISPR/Cas9-based gene-edited therapy (exa-cel, formerly known as CTX001(TM)), which entitles MaxCyte to receive platform licensing fees and program related revenue.

[nanopayments] 09/9/2022 15:00

Opex increased by 60% YoY in Q2 2022 as MaxCyte invested in manufacturing capacity and hired more field scientists and sales people. I think that says a lot about what the company thinks about future demand.